Off-label use of rituximab in dermatology: pemphigus treatment

• Päätekijät: Lislaine Bomm (Tekijä), Tainá Scalfoni Fracaroli (Tekijä), João Luz Sodré (Tekijä), Aline Bressan (Tekijä), Alexandre Carlos Gripp (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Sociedade Brasileira de Dermatologia, 2013-08-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Since its approval in 1997 by the FDA (United States Food and Drug Administration), rituximab has been used for certain B-cell lymphomas and treatment-resistant rheumatoid arthritis. Nevertheless, over the past 14 years, many case reports have demonstrated the efficacy of off-label rituximab in seve...